Hepatocellular Carcinoma
Conditions
Brief summary
This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma. The main purposes of this study include: ① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore. ② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.
Interventions
DRUGAnti-GPC3-IRDye800CW
Drug Injection: Anti-GPC3-IRDye800CW
Sponsors
Chinese Academy of Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. Patients who have been diagnosed with hepatocellular carcinoma. 2. Planned to receive hepatectomy. 3. Liver function Child-Pugh A/B. 4. GPC-3 was validated highly expressed preoperatively. 5. Aged 18 to 75, and the expected lifetime is longer than 6 months. 6. Approved to sign the informed consent.
Exclusion criteria
1. Allergic to IRDye800. 2. Enrolled in other trials in the past 3 months. 3. Another malignant tumor was found. 4. Undesirable function of heart, lung, kidney, or any other organs. 5. Unable to tolerate a hepatectomy. 6. The researchers considered inappropriate to be included.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HCC lesions | During hepatocellular resection surgery. | Numbers of intraoperatively detected hepatocellular carcinoma lesions. |
Countries
China
Contacts
Primary ContactZeyu Zhang, Ph.D.
Outcome results
None listed